Sangamo Therapeutics Inc (NASDAQ:SGMO) saw a downside of -4.82% to close Friday at $0.77 after subtracting -$0.04 on the day. The 5-day average trading volume is 1,213,660 shares of the company’s common stock. It has gained $0.9900 in the past week and touched a new high 1 time within the past 5 days. An average of 1,269,460 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,366,678.
SGMO’s 1-month performance is -14.96% or -$0.1372 on its low of $0.7625 reached on 09/22/23. The company’s shares have touched a 52-week low of $0.77 and high of $5.27, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, SGMO has lost -75.43% or -$2.3685 and has reached a new high 6 times. However, the current price is down -85.36% from the 52-week high price.
Valuation Metrics
SGMO stock has a beta of 1.13. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.63 while the price-to-book (PB) in the most recent quarter is 0.58.
Sangamo Therapeutics Inc’s quick ratio for the period ended June 29 was 2.97, with the current ratio over the same period at 2.97. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.16, while the total debt to equity was 0.16. In terms of profitability, the gross margin trailing 12 months is 93.53%. The trailing 12-month EBITDA margin is -169.97% while for the period ending June 29, Sangamo Therapeutics Inc’s operating margin was -46.05%. The firm’s gross profit as reported stood at $312.58 million against revenue of $111.3 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 62.3% to -$114.51 million, while revenue of $21.13 million was 118.45% off the previous quarter. Analysts expected SGMO to announce -$0.34 per share in earnings in its latest quarter, but it posted -$0.66, representing a -94.10% surprise. EBITDA for the quarter stood at more than -$66.86 million. SGMO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 91.43 million, with total debt at $36.37 million. Shareholders hold equity totaling $177.11 million.
Let’s look briefly at Sangamo Therapeutics Inc (SGMO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 29.65% to suggest the stock is trending oversold, with historical volatility in this time period at 94.01%.
The stock’s 5-day moving average is $0.8274, reflecting a -22.80% or -$0.2278 change from its current price. SGMO is currently trading -12.33% above its 20-day SMA, -48.91% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -46.42% and SMA200 by-78.21%.
Stochastic %K and %D was 4.74% and 5.98% and the average true range (ATR) pointed at 0.0819. The RSI (14) points at 33.97%, while the 14-day stochastic is at 2.32% with the period’s ATR at 0.0829. The stock’s 9-day MACD Oscillator is pointing at -0.1021 and -0.1150 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Sangamo Therapeutics Inc (NASDAQ: SGMO), BofA Securities downgraded it to an Underperform rating. They previously had a Neutral rating on the stock. Analysts offering their rating for SGMO stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate SGMO as a “sell,”, while 2 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 1 rates the stock as overweight while 7 have offered a “buy” rating.
What is SGMO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.50 and a high of $10.00, with their median price target at $6.00. Looking at these predictions, the average price target given by analysts is for Sangamo Therapeutics Inc (SGMO) stock is $6.01.
